Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Eric Blanchard
Eric W. Blanchard
Partner
New York +1 212 841 1111 eblanchard@cov.com Download V-card

Eric Blanchard is a partner resident in the firm’s New York office and is a vice chair of the Capital Markets and Securities Practice Group. Mr. Blanchard regularly represents companies in the pharmaceutical and life sciences industries. Mr. Blanchard advises companies and investment banks on initial public offerings, follow-on equity offerings, pre-IPO financings, investment grade debt offerings, liability management transactions, proxy contests, and acquisitions.

Mr. Blanchard regularly represents public companies with securities and disclosure issues and corporate governance matters.

The Legal 500 US describes Mr. Blanchard as “very proactive with a deep knowledge of securities law.”

IPOs and Follow-on Equity

Issuer Representations

  • REGENXBIO Inc. in a follow-on offering of common stock.
  • Oxford Immunotec Global PLC in a follow-on offering of common stock.
  • MacroGenics, Inc. in a registered direct offering and at the market program.
  • Acorda Therapeutics, Inc. in a private placement of common stock.

Underwriter Representations

  • The underwriters in the IPOs of Erytech Pharma S.A., Nightstar Therapeutics plc, UroGen Pharma Ltd, Nabriva Therapeutics AG, Cidara Therapeutics, Inc., Bellicum Pharmaceuticals, Inc., Affimed N.V., Avalanche Biotechnologies, Inc., uniQure N.V. and NeuroDerm Ltd.
  • The underwriters in the follow-on offerings of Adaptimmune Therapeutics, Affimed N.V., Avalanche Biotechnologies, Inc., Bellicum Pharmaceuticals, Inc., Exact Sciences Corporation, RedHill Biopharma Ltd., uniQure N.V. and NeuroDerm Ltd.

Investment Grade Debt

Issuer Representations

  • Bristol-Myers Squibb Company in multiple offerings of investment-grade notes.
  • Zoetis Inc. in multiple offerings of investment-grade notes.
  • Johnson & Johnson in multiple offerings of investment-grade notes.

Underwriter Representations

  • The underwriters in numerous offerings of investment-grade notes of Jefferies Group.
  • The underwriters in several offerings of investment-grade notes of The Clorox Company.
  • The underwriters in numerous public and private offerings of investment-grade notes of Cardinal Health, Inc.

Convertible Debt

Issuer Representations

  • Illumina, Inc. in multiple private offering of convertible notes pursuant to Rule 144A and Regulation S.
  • Acorda Therapeutics, Inc. in a public offering of convertible notes.
  • Avid Technology, Inc. in a private offering of convertible notes pursuant to Rule 144A.
  • Central European Media Enterprises, Ltd. in an exchange of newly issued convertible notes for outstanding convertible notes conducted pursuant to Section 3(a)(9) of the Securities Act.

Underwriter Representations

  • The underwriters in a contemporaneous public offering of convertible notes and common stock of Gevo, Inc.

Governance Matters

  • Illumina, Inc. in connection with a successful proxy defense relating to a hostile takeover bid by Roche.
  • The Board of Trustees of The Ohio State University in connection with a university-wide assessment of the institution’s compliance program, which led to the establishment of a novel Office of University Compliance and Integrity.
  • A large private equity firm in connection with a review of the governance and compliance programs of several of the firm’s portfolio companies.
  • The independent directors of a large life sciences company in connection with corporate governance and compliance matters.

Memberships and Affiliations

  • Association of the Bar of the City of New York, Financial Reporting Committee
  • Society of Corporate Secretaries and Governance Professionals
  • American Bar Association
  • Legal 500 US, Finance - Capital Markets (2010-2017)